Open Access Article
This Open Access Article is licensed under a
Creative Commons Attribution 3.0 Unported Licence

Novel α-N-heterocyclic thiosemicarbazone complexes: synthesis, characterization, and antimicrobial of properties investigation

Dilek Nartopa, Elvan Hasanoğlu Özkan*b, Hatice Öğütcüc, Nurdan Kurnaz Yetimd and İnci Özdemire
aDepartment of Chemistry, Faculty of Arts and Sciences, Düzce University, Düzce, Turkiye
bDepartment of Chemistry, Faculty of Sciences, Gazi University, Ankara, Turkiye. E-mail: ehasanoglu@gazi.edu.tr
cDepartment of Field Crops, Faculty of Agriculture, Kırşehir Ahi Evran University, Kırşehir, Turkiye
dDepartment of Chemistry, Faculty of Arts and Sciences, Kırklareli University, Kırklareli, Turkiye
eKocaeli University, Izmit Vocational School, Property Protection and Security Department, 41285, Kocaeli, Turkiye

Received 31st May 2024 , Accepted 10th September 2024

First published on 16th September 2024


Abstract

In this paper, eight novel α-N-heterocyclic thiosemicarbazone complexes were synthesized in search of new biologically active compounds, and characterized via organic elemental analysis, nuclear magnetic resonance spectroscopy, infrared spectra, thermogravimetric analysis, ultraviolet-visible spectroscopy, molar conductance and magnetic susceptibility measurements. The in vitro antimicrobial activity of these complexes was examined against ten disease-causing pathogens: Gram-positive bacteria (Micrococcus luteus ATCC9341, Staphylococcus epidermidis ATCC12228, Bacillus cereus RSKK863) and Gram-negative bacteria (Pseudomonas aeroginosa ATCC27853, Klebsiella pneumonia ATCC27853, Enterobacter aerogenes ATCC51342, Salmonella typhi H NCTC9018394, Shigella dysenteria NCTC2966, Proteus vulgaris RSKK96026) and yeast (Candida albicans Y-1200-NIH). The results revealed that the α-N-heterocyclic thiosemicarbazone compounds showed potent activity. It was observed that all thiosemicarbazone complexes were more susceptible to Gram-negative strains based on the presence of an electron-withdrawing substituent (–Br/–Cl/–F). It was determined that thiosemicarbazone Cu2+complexes showed stronger antifungal effects.


1 Introduction

Heterocyclic compounds are organic structures in which some carbon atoms are replaced by heteroatoms such as nitrogen, sulphur, oxygen, and phosphorus.1 Heterocyclics have different physical and chemical properties and reactivity depending on the heteroatoms' ring size and structure.2 Recently, there has been an increasing interest in heterocyclic compounds due to their various applications. The synthesis of innovative, stereo-selective, functional new heterocyclic compounds is of great interest for drug discovery and development.3 Heterocyclic compounds are used in the agrochemical industry in crop protection due to their pesticidal activities.4 Heterocycles are used in the pharmaceutical industry to treat some diseases (such as Alzheimer's, cancer, diabetes, circulatory diseases, and AIDS) due to their therapeutic properties.5 Heterocycles bind with enzymes due to their variety of intermolecular interaction properties. These properties of heterocycles are the reasons for preference in anti-cancer drug design.6 Particularly, thiosemicarbazone-based heterocyclics are an important class of heterocyclic compounds because of their coordination capacity. 7 They are important chelating ligands due to the containing potential donor atoms (deprotonated phenolic oxygen, thione/thiol sulphur, azomethine nitrogen, etc.).8 Especially, α-N-heterocyclic thiosemicarbazones, in which the thiosemicarbazone side chain is linked to an N-heterocyclic ring at the α position, are strong metal chelating agents.9 Heterocyclic compounds containing thiosemicarbazone have various biological, cytotoxic, and pharmacological activities. These properties of thiosemicarbazones are generally related to the presence of imine group (–N[double bond, length as m-dash]CH–) and metal ion coordination. The coordination affects such properties as lipophilicity, drug resistance, etc.10–12 The complexes can exhibit bioactivities not shown by the free ligands.13 Heterocyclic thiosemicarbazones and their metal complexes exhibit a broad range of activities such as antibacterial, antioxidant, antitumor, antimicrobial, antiviral, antifungal, antimalarial, anticonvulsant, anti-HIV, antiamoebic, antiproliferative, anti-inflammatory, antidiabetic, and anticancer.14–18 Heterocyclic thiosemicarbazone complexes of nickel metal play an important role in the biology of microorganisms and plants, have variable binding modes, and show strong biological, antibacterial, and inhibitory activity.10,19–22 Heterocyclic thiosemicarbazone complexes of copper, which catalysed redox reactions and are essential for life and the most effective available divalent ion for binding to organic compounds, strong exhibit antibacterial, antitumor, anticancer, and antimicrobial activity.23–26 Thiosemicarbazone transition metal complexes have been reported as extensively effective and preferred drugs.27,28 The synthesis of new heterocyclic thiosemicarbazone metal complexes is important due to their biological and pharmacological properties. Therefore, novel α-N-heterocyclic thiosemicarbazone complexes were synthesized using thiosemicarbazide, carboxaldehyde, aldehyde derivatives, and metal salts.

It is predicted that the new heterocyclic thiosemicarbazone Ni2+ and Cu2+ complexes synthesized within the scope of this study will contribute to the importance of heterocyclic chemistry in the pharmaceutical industry and medicinal chemistry.

2 Experimental

2.1. Materials and measurements

All chemicals were procured from Sigma-Aldrich. Organic elemental analyses were obtained with a Thermo-Scientific Flash-2000 model elemental analyzer. IR spectra were recorded from KBr pellets using a Shimadzu IR Prestige-21 model spectrometer. 1H-NMR spectra were measured on a Bruker Biospin brand Avance III 400 MHz model device. UV-Vis spectra were determined on a UV-1800 ENG240V, Soft model spectrophotometer. TGA analysis were carried out using a Shimadzu DTG 60H-DSC 60 model thermal analyzer. The molar conductance of complexes was measured in dimethyl sulphoxide (DMSO) at 21 °C on Conductivity 430 Lab. Magnetic measurements were obtained with a Sherwood Scientific MKI model Evans magnetic susceptibility device.

2.2. Synthesis of heterocyclic compounds containing thiosemicarbazone

All heterocyclic thiosemicarbazone Ni2+ and Cu2+ complexes were prepared with the template method (Fig. 1 and 2). Novel heterocyclic thiosemicarbazone complexes (H1Ni, H2Ni, H3Ni, H4Ni, H1Cu, H2Cu, H3Cu, and H4Cu) were synthesized by the reaction of 4-phenyl-thiosemicarbazide (4 mmol) and 2-aminothiazole-5-carboxaldehyde (4 mmol) in ethanol/DMSO mixture. The pH of the solution was adjusted to 5–5.5 with 1 mL of acetic acid. The solution was heated with stirring under reflux for 5 h at 80 °C. The ethanol solution (50 mL) of the salicylaldehyde derivatives (4 mmol) was added to the mixture and stirred for a further 5 h at 80 °C. 5-Fluoro-3-methylsalicylaldehyde, 5-bromo-salicylaldehyde, 3-chloro-5-fluorosalicylaldehyde, and 5-methylsalicylaldehyde were used as salicylaldehyde. The ethanol solution (5 mL) of the metal salts [nickel(II) chloride hexahydrate & copper(II) chloride (anhydrous)] was added dropwise to the reaction mixture and stirred by refluxing for a further 4 h at 70 °C. The mixture was evaporated at room temperature. The colored product was filtered, purified, and dried.
image file: d4ra04002c-f1.tif
Fig. 1 General procedure for the heterocyclic thiosemicarbazone (a) Cu complexes (H1Cu, H2Cu) and (b) Ni complexes (H1Ni, H2Ni).

image file: d4ra04002c-f2.tif
Fig. 2 General procedure for the heterocyclic thiosemicarbazone (a) Cu complexes (H3Cu, H4Cu) and Ni complexes H3Ni, H4Ni).

The structures of all heterocyclic thiosemicarbazone complexes (H1Ni, H2Ni, H3Ni, H4Ni, H1Cu, H2Cu, H3Cu, and H4Cu) were determined by spectroscopic techniques.

2.2.1 H1Ni. Yield 0.3503 g (69%), burgundy solid, mp 192 °C. IR spectrum (KBr), ν, cm−1: 3340 (OH); 829 (H2O); 3025 (CH)aro.; 1615 (CH[double bond, length as m-dash]N); 1544 (CH[double bond, length as m-dash]N)tyz; 1495 (C[double bond, length as m-dash]C); 1210, 819 (C[double bond, length as m-dash]S); 750 (C–S–C); 1003 (N–N); 3243 (N–H); 568 (M–O); 492 (M–N). 1H-NMR spectrum (400 MHz, DMSO-d6), δ, ppm: 11.71 (1H, s, N–NH), 10.91 (1H, s, Ar–OH), 8.94 (1H, s, CH[double bond, length as m-dash]N), 6.87–7.50 (5H, m, Ar–H), 2.27 (3H, s, Ar–CH3). Elemental analysis found%: C 44.28; H 3.75; N 13.45; S 13.06. C19H19N5S2O2ClNi. Calculated, %: C 43.46; H 3.26; N 13.34; S 12.21, UV-Vis (DMSO, ε × 10−4 M), λmax, nm: 383, 663.
2.2.2 H1Cu. Yield 0.3010 g (61%), dark burgundy solid, mp 180 °C. IR spectrum (KBr), ν, cm−1: 3345 (OH); 3078 (CH)aro.; 1616 (CH[double bond, length as m-dash]N); 1520 (CH[double bond, length as m-dash]N)tyz; 1475 (C[double bond, length as m-dash]C); 1207, 815 (C[double bond, length as m-dash]S); 738 (C–S–C); 1017 (N–N); 3247 (N–H); 559 (M–O); –(M–N). Elemental analysis found%: C 47.17; H 3.19; N 14.21; S 13.04. C19H16N5S2OClCu. Calculated, %: C 46.24; H 3.27; N 14.19; S 12.99, UV-Vis (DMSO, ε × 10−4 M), λmax, nm: 441, 889.
2.2.3 H2Ni. Yield 0.4120 g (72%), burgundy solid, mp 197 °C. IR spectrum (KBr), ν, cm−1: 3337 (OH); 770 (H2O); 3049 (CH)aro.; 1603 (CH[double bond, length as m-dash]N); 1520 (CH[double bond, length as m-dash]N)tyz; 1475 (C[double bond, length as m-dash]C); 1210, 820 (C[double bond, length as m-dash]S); 750 (C–S–C); 1014 (N–N); 3231 (N–H); 574 (M–O); 501 (M–N). 1H-NMR spectrum (400 MHz, DMSO-d6), δ, ppm: 11.46 (1H, s, N–NH), 10.45 (1H, s, Ar-OH), 8.18 (1H, s, CH[double bond, length as m-dash]N), 6.95–7.69 (5H, m, Ar–H). Elemental analysis found%: C 38.01; H 2.64; N 12.27; S 11.17. C18H16N5S2O2ClBrNi. Calculated, %: C 36.65; H 2.39; N 11.87; S 10.87, UV-Vis (DMSO, ε × 10−4 M), λmax, nm: 380, 660.
2.2.4 H2Cu. Yield 0.3629 g (65%), dark burgundy solid, mp 185 °C. IR spectrum (KBr), ν, cm−1: 3330 (OH); 3065 (CH)aro.; 1615 (CH[double bond, length as m-dash]N); 1506 (CH[double bond, length as m-dash]N)tyz; 1471 (C[double bond, length as m-dash]C); 1212, 817 (C[double bond, length as m-dash]S); 747 (C–S–C); 1011 (N–N); 3228 (N–H); 596 (M–O); 479 (M–N). Elemental analysis found%: C 38.42; H 2.22; N 12.49; S 11.37. C18H13N5S2OClBrCu. Calculated, %: C 38.72; H 2.35; N 12.54; S 11.48, UV-Vis (DMSO, ε × 10−4 M), λmax, nm: 431, 887.
2.2.5 H3Ni. Yield 0.3222 g (59%), burgundy solid, mp 201 °C. IR spectrum (KBr), ν, cm−1: 3317 (OH); 781 (H2O); 3080 (CH)aro.; 1616 (CH[double bond, length as m-dash]N); 1503 (CH[double bond, length as m-dash]N)tyz; 1456 (C[double bond, length as m-dash]C); 1208, 821 (C[double bond, length as m-dash]S); 751 (C–S–C); 1006 (N–N); 3219 (N–H); 562 (M–O); 490 (M–N). 1H-NMR spectrum (400 MHz, DMSO-d6), δ, ppm: 11.66 (1H, s, N–NH), 10.59 (1H, s, Ar–OH), 8.22 (1H, s, CH[double bond, length as m-dash]N), 7.02–7.68 (5H, m, Ar–H), 2.27 (3H, s, Ar–CH3). Elemental analysis found%: C 38.99; H 2.67; N 12.87; S 11.66. C18H15N5S2O2FCl2Ni. Calculated, %: C 38.37; H 2.33; N 12.43; S 11.38, UV-Vis (DMSO, ε × 10−4 M), λmax, nm: 379, 661.
2.2.6 H3Cu. Yield 0.3191 g (60%), dark burgundy solid, mp 189 °C. IR spectrum (KBr), ν, cm−1: 3321 (OH); 3078 (CH)aro.; 1612 (CH[double bond, length as m-dash]N); 1505 (CH[double bond, length as m-dash]N)tyz; 1453 (C[double bond, length as m-dash]C); 1205, 825 (C[double bond, length as m-dash]S); 751 (C–S–C); 1009 (N–N); 3223 (N–H); 561 (M–O); 488 (M–N). Elemental analysis found%: C 39.95; H 2.30; N 13.21; S 12.19. C18H12N5S2OFCl2Cu. Calculated, %: C 40.65; H 2.27; N 13.17; S 12.06, UV-Vis (DMSO, ε × 10−4 M), λmax, nm: 428, 893.
2.2.7 H4Ni. Yield 0.3312 g (63%), burgundy solid, mp 192 °C. IR spectrum (KBr), ν, cm−1: 3331 (OH); 792 (H2O); 3063 (CH)aro.; 1621 (CH[double bond, length as m-dash]N); 1501 (CH[double bond, length as m-dash]N)tyz; 1456 (C[double bond, length as m-dash]C); 1203, 842 (C[double bond, length as m-dash]S); 749 (C–S–C); 1005 (N–N); 3244 (N–H); 570 (M–O); 485 (M–N). 1H-NMR spectrum (400 MHz, DMSO-d6), δ, ppm: 11.25 (1H, s, N–NH), 10.61 (1H, s, Ar-OH), 8.29 (1H, s, CH[double bond, length as m-dash]N), 7.11–7.82 (5H, m, Ar–H). Elemental analysis found%: C 43.55; H 3.71; N 13.51; S 12.49. C19H18N5S2O2FClNi. Calculated, %: C 42.02; H 2.97; N 12.90; S 11.81, UV-Vis (DMSO, ε × 10−4 M), λmax, nm: 377, 659.
2.2.8 H4Cu. Yield 0.2813 g (55%), dark burgundy solid, mp 187 °C. IR spectrum (KBr), ν, cm−1: 3325 (OH); 3078 (CH)aro.; 1616 (CH[double bond, length as m-dash]N); 1503 (CH[double bond, length as m-dash]N)tyz; 1456 (C[double bond, length as m-dash]C); 1208, 842 (C[double bond, length as m-dash]S); 753 (C–S–C); 1015 (N–N); 3241 (N–H); 575 (M–O); 504 (M–N). Elemental analysis found%: C 44.79; H 2.99; N 13.21; S 13.01. C19H15N5S2OFClCu. Calculated, %: C 44.62; H 2.96; N 13.69; S 12.54, UV-Vis (DMSO, ε × 10−4 M), λmax, nm: 429, 891.

2.3. Antimicrobial assay

Gram (+) bacteria, Gram (–) bacteria and yeast used in the antimicrobial study are as follows, respectively: (Micrococcus luteus ATCC9341, Staphylococcus epidermidis ATCC12228, Bacillus cereus RSKK863), (Pseudomonas aeroginosa ATCC27853, Klebsiella pneumonia ATCC27853, Enterobacter aerogenes ATCC51342, Salmonella typhi H NCTC9018394, Shigella dysenteria NCTC2966, Proteus vulgaris RSKK96026) and (Candida albicans Y-1200-NIH). For the antimicrobial assay, all heterocyclic thiosemicarbazone complexes (H1Ni, H2Ni, H3Ni, H4Ni, H1Cu, H2Cu, H3Cu, and H4Cu) were screened against these disease agent pathogens by the well-diffusion methods.29–31 In this method, it was determined that DMSO, used as solvent control, did not show antimicrobial activity against the tested organisms. As a first step, all heterocyclic thiosemicarbazone complexes were solved (3.5 μg mL−1) in DMSO, and all pathogenic microorganisms were incubated in Nutrient Broth agar (106 CFU mL−1) for 24 h at 37 °C. As a second step, these cultures were then homogenized by adding them to Mueller–Hinton Agar (MHA) cooled to 45 °C, and they were poured into sterile Petri dishes and cooled. Afterward, wells of 6 mm diameter were pierced in these agars, and the heterocyclic thiosemicarbazone complexes were added. Finally, the plates were incubated in an oven (at 37 °C, 24 h), the inhibition zone of all heterocyclic compounds was measured, and then the average of the activity values performed with two repetitions was taken. As a third second, selected disease agent pathogens were compared with standard antibiotics. For this purpose, Ampicillin (AMP10), Sulphamethoxazole (SXT25), Amoxicillin (AMC30), and Kanamycin (K30) antibiotics were used for Gram (+) and Gram (–) bacteria, and Nystatin (NYS100) antibiotic was used for yeast.

3 Results

3.1. Characterization of heterocyclic compounds containing thiosemicarbazone

Some physical properties, analytical, and organic elemental analysis data of all heterocyclic thiosemicarbazone Ni2+ and Cu2+ complexes are presented in Table 1. It was defined that the elemental analyses and the chemical formulas of all heterocyclic thiosemicarbazone complexes were compatible.
Table 1 Some physical properties, analytical and organic elemental analysis data of heterocyclic thiosemicarbazone complexesa
Symbol Chemical formula (Mw, g mol−1) Colour conductance (μS cm−1) M. p. (°C) Elemental analysis calculated (found)%
μeff (BM) C H N S
a D: diamagnetic.
H1Ni C19H17N5S2OCl2Ni Burgundy 192 44.95 3.77 13.80 12.63
(525.09) 35.6 D (43.46) (3.26) (13.34) (12.21)
H1Cu C19H16N5S2OClCu Dark burgundy 180 46.24 3.27 14.19 12.99
(493.49) 15.4 1.93 (47.17) (3.19) (14.21) (13.04)
H2Ni C18H14N5S2OCl2BrNi Burgundy 197 37.76 2.82 12.23 11.20
(586.86) 2.5 D (36.65) (2.39) (11.87) (10.87)
H2Cu C18H13N5S2OClBrCu Dark burgundy 185 38.72 2.35 12.54 11.48
(558.36) 15.6 1.81 (38.42) (2.22) (12.49) (11.37)
H3Ni C18H13N5S2OFCl3Ni Burgundy 201 39.59 2.77 12.83 11.74
(563.50) 21.8 D (38.37) (2.33) (12.43) (11.38)
H3Cu C18H12N5S2OFCl2Cu Dark burgundy 189 40.65 2.27 13.17 12.06
(531.89) 17.0 2.11 (39.95) (2.30) (13.21) (12.19)
H4Ni C19H16N5S2OFCl2Ni Burgundy 192 43.41 3.45 13.32 12.20
(543.48) 9.0 D (42.02) (2.97) (12.90) (11.81)
H4Cu C19H15N5S2OFClCu Dark burgundy 187 44.62 2.96 13.69 12.54
(511.48) 55.7 1.98 (44.79) (2.99) (13.21) (13.01)


IR spectra data of all heterocyclic thiosemicarbazone Ni2+ and Cu2+ complexes are presented in Table 2 and are shown in Fig. S1. In the infrared spectra of all complexes, absorption bands were observed in 1003–1017 cm−1 and 3219–3247 cm−1 ranges, which were assigned to the ν(N–N) and ν(N–H) vibrations, respectively. The stretching vibrations of ν(CH[double bond, length as m-dash]N) belonging to the azomethine groups obtained by the condensation reaction of aldehydes and amines, were observed in the 1603–1621 cm−1 and 1501–1544 cm−1 ranges, respectively. The absorption bands assigned to ν(C[double bond, length as m-dash]C) and ν(CH) of the aromatic ring were observed in the 1453–1495 cm−1 and 3025–3080 cm−1 ranges, respectively. The stretching vibrations of ν(C–S–C) belonging to the thiazole groups were determined in the 738–753 cm−1 region. The stretching vibrations of ν(C[double bond, length as m-dash]S) vibrations occurred in the 815–842 cm−1 and 1203–1212 cm−1 ranges, respectively. Additionally, the observation of bands in the ranges 479–504 cm−1 and 559–596 cm−1 was due to the stretching vibrations of ν(M–N) and ν(M–O). 32 These bands indicate the coordination of ligands to metal centers.

Table 2 FT-IR spectra data of heterocyclic thiosemicarbazone complexes
Symbol ν(OH) ν(CH)aro./ν(C[double bond, length as m-dash]C) ν(CH[double bond, length as m-dash]N)/ν(CH[double bond, length as m-dash]N)tyz ν(C[double bond, length as m-dash]S) ν(C–S–C) ν(N–N)/ν(N–H) ν(M–O)/ν(M–N)
H1Ni 3340 3025 1615 1210 750 1003
1495 1544 819 3243 492
H1Cu 3078 1616 1207 738 1017 559
1475 1520 815 3247 490
H2Ni 3337 3049 1603 1210 750 1014
1475 1520 820 3231 501
H2Cu 3065 1615 1212 747 1011 596
1471 1506 817 3228 479
H3Ni 3317 3080 1616 1208 751 1006
1456 1503 821 3219 490
H3Cu 3078 1612 1205 751 1009 561
1453 1505 825 3223 488
H4Ni 3331 3063 1621 1203 749 1005
1456 1501 842 3244 485
H4Cu 3078 1616 1208 753 1015 575
1456 1503 842 3241 504


1H-NMR spectra data of all heterocyclic thiosemicarbazone Ni2+ complexes are presented in Table 3 and are shown in Fig. S2. In the spectra of all complexes, NH protons (N–NH) appeared in the range of 1066–1171 ppm. Unsymmetric azomethine (CH[double bond, length as m-dash]N) peaks obtained by the condensation reaction of aldehydes and amines were observed in the 8.18–8.94 ppm region. The phenolic protons (Ar–OH) and aromatic protons (Ar–H) occurred in the regions 10.45–10.91 ppm and 6.87–7.82 ppm, respectively. In addition, for H1Ni and H3Ni, the methyl protons (Ar–CH3) were also detected at 2.27 ppm.33

Table 3 1H-NMR chemical shift (ppm) of heterocyclic thiosemicarbazone Ni(II) complexes
Compound N–NH Ar–OH CH[double bond, length as m-dash]N Ar–H Ar–CH3
H1Ni 11.71 10.91 8.94 6.87–7.50 2.27
H2Ni 11.46 10.45 8.18 6.95–7.69
H3Ni 10.66 10.59 8.22 7.02–7.68 2.27
H4Ni 11.25 10.61 8.29 7.11–7.82


TGA analysis data of all heterocyclic thiosemicarbazone Ni2+ and Cu2+ complexes are presented in Table 4 and are shown in Fig. S3. Thermal decomposition curves of nickel complexes show that H1Ni and H2Ni exhibited two-stage weights, while H3Ni and H4Ni exhibit three-stage weights. The thermal degradation curves of copper complexes show that H2Cu exhibited two-stage weights, H1Cu and H3Cu exhibited three-stage weights, and H4Cu exhibited four-stage weights. The residues at the end of the decomposition for all complexes were determined in the range of 2.12–6.533.41–12.57% and indicated NiO and CuO, respectively.

Table 4 TGA and UV-Vis data of heterocyclic thiosemicarbazone complexes
Compound Charge transfer transition (nm) d–d transition (nm) Step Ti (°C) Tf (°C) Residue mass at 800 °C (wt%)
H1Ni 383 663 1st 115.02 261.31 3.46
2nd 320.89 408.36
3rd 437.02 624.15
H1Cu 441 889 1st 106.89 166.67 3.41
2nd 223.70 386.71
3rd 471.22 644.75
H2Ni 380 660 1st 110.14 208.30 6.05
2nd 214.18 391.47
3rd 488.93 670.19
H2Cu 431 887 1st 121.79 387.13 5.32
2nd 494.24 678.22
H3Ni 379 661 1st 158.26 342.89 6.53
2nd 410.75 709.38
H3Cu 428 893 1st 102.86 203.77 3.84
2nd 253.80 422.66
3rd 482.08 691.43
H4Ni 377 659 1st 111.95 351.47 2.12
2nd 394.44 620.19
H4Cu 429 891 1st 101.57 200.36 12.17
2nd 267.10 462.03
3rd 490.31 544.63
4th 553.66 687.51


UV-Vis spectra data of all heterocyclic thiosemicarbazone Ni2+ and Cu2+ complexes are presented in Table 4. The electronic spectra of all nickel and copper complexes showed two main bands. π → π* transitions of the aromatic ring and n → π* transitions of the imine group were observed in the ranges of 231–252 nm and 323–327 nm, respectively. In the electronic spectra of nickel complexes, the absorption bands that appeared in the 377–383 nm range were assigned to metal–ligand charge transfer transitions. The bands observed in the 659–663 nm range were assigned to the d–d transitions, which is compatible with the Ni2+ square planar geometry.34 In the electronic spectra of copper complexes, the absorption bands observed in the 428–441 nm range were assigned to intra-ligand charge transfer transitions.35 The bands that appeared in the 887–893 nm range were assigned to the d–d transitions, which is compatible with the Cu(II) tetrahedral geometry.36

The magnetic moments of heterocyclic thiosemicarbazone Ni2+ complexes were determined diamagnetic, confirming the existence of square planar geometry.37 The magnetic moments of heterocyclic thiosemicarbazone Cu2+ complexes were observed in the range of 1.81–2.11 B.M., indicating the presence of one unpaired electron in the Cu2+ ion.38 The paramagnetic behavior confirms the existence of tetrahedral geometry.39

The molar conductance of heterocyclic thiosemicarbazone Ni2+ and Cu2+ complexes was determined in the range 2.5–35.6 μS cm−1 and 15.4–55.7 μS cm−1, respectively, confirming the non-electrolyte nature of all complexes in DMSO solution.40

The graphical illustration and the photographs of inhibition regions of pathogenic bacterial species are presented in Fig. 3–5, respectively. The heterocyclic thiosemicarbazone Ni2+ and Cu2+ complexes' were tested in vitro against selected disease-causing pathogenic bacteria and yeast to determine their antibacterial and antifungal activities. The yeast and pathogens were compared to the standard antibiotics and anticandidal. The results showed that the compounds had different antimicrobial effects against Gram-positive bacteria (M. luteus, S. epidermidis, B. cereus), Gram-negative bacteria (P. aeroginosa, K. pneumonia, E. aerogenes, S. typhi H, S. dysenteria, P. vulgaris) and yeast (C. albicans). The heterocyclic thiosemicarbazone Ni2+and Cu2+ complexes generally exhibited more potent antibacterial capacity against Gram (–) than Gram (+) bacteria. H2Ni (29 mm) complex showed more higher inhibitory effects than all standard antibiotics against the Gram (+) bacteria B. cereus. This pathogen causes certain infections such as vomiting and eye.41 H3Cu and H2Ni complexes (24 mm and 25 mm, respectively) demonstrated higher activity than the standard antibiotics (except AMC30) against the Gram (+) bacteria M. luteus. This pathogen causes bloodstream infections.42 Among Gram (–) bacteria, all heterocyclic thiosemicarbazone complexes (16–25 mm) showed significant antibacterial activities against P. aeroginosa and S. typhi H compared to the standard antibiotics. S. typhi H bacteria causes typhoid.43 H2Ni (25 mm), H2Cu (21 mm), H3Cu (22 mm) complexes showed a more potent inhibitory impact than all standard antibiotics against P. aeroginosa. This bacteria causes urinary tract infections.44 H3Cu (23 mm) demonstrated a potent antibacterial activity than all standard antibiotics against P. vulgaris. This pathogen causes certain infections, such as meningitis, diarrhea, and abscesses.45 H1Cu (25 mm) showed more higher activity than all standard antibiotics against E. aerogenes. This pathogen causes infections in the urinary and respiratory tracts.46 Additionally, the antifungal effects of the heterocyclic thiosemicarbazone Ni2+ and Cu2+ complexes were compared to the standard Nystatin antibiotic against yeast C. albicans. This fungus causes gastrointestinal tract infections and bloodstream infections.47 Cu2+ complexes generally exhibited a more potent effect than Ni2+ complexes. H3Cu (27 mm), H1Cu (25 mm), and H2Cu (23 mm) complexes showed much stronger antifungal activity than Nystatin. H1Ni (20 mm) and H2Ni (20 mm) complexes demonstrated as much inhibitory impact as standard antibiotics.


image file: d4ra04002c-f3.tif
Fig. 3 Graphical illustration of Gram (+) pathogenic bacterial species, and standard antibiotics.

image file: d4ra04002c-f4.tif
Fig. 4 Graphical illustration of Gram (–) pathogenic bacterial species, and standard antibiotics.

image file: d4ra04002c-f5.tif
Fig. 5 Photographs of inhibition zones (mm) of some Gram (+) and Gram (–) bacteria.

In conclusion, the heterocyclic thiosemicarbazone Ni2+ and Cu2+ complexes were determined to have high or moderate antifungal and antibacterial activity. It was observed that the antibacterial and antifungal activities of thiosemicarbazone compounds, including electron-withdrawing groups (–Br/–Cl/–F), were more effective than the thiosemicarbazone compounds, including electron-donating group (–CH3). The synthesized thiosemicarbazone compounds showed very good antibacterial and antifungal properties because they contain thiazole rings containing N and S heteroatoms, nickel and copper metal ions with chelation ability, and asymmetric diimine groups that impart biological activity. This situation is consistent with similar research results.24,48,49 The antimicrobial activities vary depending on the presence of metal ions, the position of the substituent on the ring, and the presence of terminal groups (–CH3, –Ph, –F, –Cl, –Br, etc.). Increased and/or decreased biological activities have been reported for compounds.27 The antimicrobial activities increase and/or decrease depending on the presence of metal ions, the position of the substituent on the ring, and the presence of terminal groups (–CH3, –Ph, –F, –Cl, –Br, etc.).

Ni2+ complexes generally showed stronger antibacterial activity than Cu2+ complexes. Especially the H2Ni complex exhibited a higher inhibitory effect.

4 Conclusions

In this study, novel α-N-heterocyclic thiosemicarbazone compounds were synthesized using the template method and were characterized by different spectroscopic techniques. Based on the spectral studies, it was determined that Ni2+ complexes had a square planar geometry, while Cu2+ complexes had tetrahedral geometry. The biological activities of heterocyclic thiosemicarbazone compounds were evaluated against disease-causing pathogens using the well-diffusion method. All heterocyclic thiosemicarbazone complexes were observed to have high or moderate antimicrobial activity. The synthesized thiosemicarbazone compounds containing asymmetric azomethine groups exhibited different biological activities depending on the presence of metal ions and the presence of terminal groups. The heterocyclic thiosemicarbazone Ni2+ and Cu2+ complexes exhibited more potent impacts against different Gram-negative bacterial strains as potential antibacterial agents. The heterocyclic thiosemicarbazone Ni2+ complexes showed more potent impacts against yeast as potential antifungal agents. According to high/or moderate biological activity results, the synthesized novel α-N-heterocyclic thiosemicarbazone compounds can be recommended as potent inhibitors in diverse pharmaceutical, biological, medicinal, biomedical, etc. applications.

Data availability

The data supporting this article have been included in the main article and the ESI.

Author contributions

D. Nartop designed the experiments and contributed to the interpretation of the results. E. Hasanoğlu Özkan carried out the experiments depend on synthesis. D. Nartop and E. Hasanoğlu Özkan performed visualization, formal analysis, writing – original draft, writing-review, and editing, H. Ogutcu carried out the antimicrobial experiments and assessments. N. Kurnaz Yetim and İ. Özdemir contributed to conceptualization and review. Each author contributed to the final manuscript and discussed the findings.

Conflicts of interest

There are no conflicts to declare between the authors.

Acknowledgements

This work was supported by the Düzce University Scientific Research Project (grant number: 2021.05.03.1215).

References

  1. D. Bandyopadhyay and B. K. Banik, Microwave-induced Synthesis of Heterocycles of Medicinal Interests: In Green Synthetic Approaches for Biologically Relevant Heterocycles, Elsevier Inc., 2015, vol. 1, pp. 517–557 Search PubMed .
  2. V. J. Ram, A. Sethi, M. Nath and R. Pratap, The Chemistry of Heterocycles: Nomenclature and Chemistry of Three to Five Membered Heterocycles, Elsevier, 2019 Search PubMed .
  3. P. A. Taylor, R. P. Robinson, Y. M. Fobian, D. C. Blakemore, L. H. Jones and O. Fadeyi, Modern advances in heterocyclic chemistry in drug discovery, Org. Biomol. Chem., 2016, 14(28), 6611–6637 Search PubMed .
  4. G. C. dos Santos, L. M. Martins, B. A. Bregadiolli, V. F. Moreno, L. C. da Silva-Filho and B. H. S. T. da Silva, Heterocyclic compounds as antiviral drugs: synthesis, structure-activity relationship and traditional applications, J. Heterocycl. Chem., 2021, 58(427), 1–35 Search PubMed .
  5. S. P. Palaniappan, Pharmacological role of heterocyclic compounds in the treatment of Alzheimer's disease: A Review, J. Phytopharm., 2022, 11(4), 289–294 Search PubMed .
  6. S. Pearce, The importance of heterocyclic compounds in anti-cancer drug design, Drug Discovery World, 2017, 18(2), 66–70 Search PubMed .
  7. S. Argibay-Otero, R. Carballo and E. M. Vázquez-López, Coordination chemistry of potentially S,N,Npy-Tridentate thiosemicarbazones with the {Re(CO)3}+ fragment and formation of hemiaminal derivatives, Inorg. Chem., 2023, 62(1), 224–237 Search PubMed .
  8. E. B. Seena, M. Sithambaresan and S. Vasudevan, et al., Structural and spectral characterization of Cu(II) complexes of N(4)-substituted thiosemicarbazones derived from 2-hydroxyacetophenone: Crystal structure of a dinuclear Cu(II) complex, J. Chem. Sci., 2020, 132(149), 1–11 Search PubMed .
  9. A. I. Matesanz and P. Souza, Unprecedented Pt(II) complex of an asymmetric 2,6-diacetylpyridine bis(4N-substituted thiosemicarbazone) ligand, Inorg. Chem. Commun., 2013, 27, 5–8 Search PubMed .
  10. F. Muleta and T. A. R. Eswaramoorthy, A Review on synthesis, characterization methods and biological activities of semicarbazone, thiosemi-carbazone and their transition metal complexes, J. Nat. Sci. Res., 2019, 9(17), 33–46 Search PubMed .
  11. N. Farrell, Biomedical uses and applications of inorganic chemistry, Coord. Chem. Rev., 2002, 232(1–2), 1–4 Search PubMed .
  12. D. West, S. Padhye and P. Sonawane, in Structure and Bonding, Springer-Verlag, New York, 1991, vol. 76, pp. 1–49 Search PubMed .
  13. F. Basuli, S. M. Peng and S. Bhattacharya, Unusual coordination mode of thiosemicarbazone ligands. a search for the origin, Inorg. Chem., 2000, 39(6), 1120–1127 Search PubMed .
  14. S. Fernández-Fariña, I. Velo-Heleno, M. Martínez-Calvo, A. M. González-Noya and R. Pedrido, Design, synthesis and structural characterization of a novel asymmetric hydrazone-thiosemicarbazone ligand with the aim of obtaining ınteresting metallosupramolecular architectures, ChemistrySelect, 2022, 8(16), 1–5 Search PubMed .
  15. D. U. Kirtani, N. S. Ghatpande, K. R. Suryavanshi, P. P. Kulkarni and A. A. Kumbhar, Fluorescent copper(II) complexes of asymmetric bis(thiosemicarbazone)s: Electrochemistry, cellular uptake and antiproliferative activity, ChemistrySelect, 2021, 6, 6063–6070 Search PubMed .
  16. N. Özdemir, M. Şahin, T. Bal-Demirci and B. Ülküseven, The asymmetric ONNO complexes of dioxouranium(VI) with N1,N4-diarylidene-S-propyl-thiosemicarbazones derived from 3,5-dichlorosalicylaldehyde: Synthesis, spectroscopic and structural studies, Polyhedron, 2011, 30(3), 515–521 Search PubMed .
  17. T. Varadinova, D. Kovala-Demertzi, M. Rupelieva, M. Demertzis and P. Genova, Antiviral activity of platinum (II) and palladium (II) complexes of pyridine-2-carbaldehyde thiosemicarbazone, Acta Virol., 2001, 45(2), 87–94 Search PubMed .
  18. S. N. Pandeya and J. R. Dimmock, Recent evaluations of thiosemicarbazones and semicarbazones and related compounds for antineoplastic and anticonvulsant activities, Pharmazie, 1993, 48(9), 659–666 Search PubMed .
  19. N. C. Kasuga, K. Sekino, C. Kuomo, N. Shimada, M. Ishikawa and K. Nomiya, Synthesis, structural characterization and antimicrobial activities of 4- and 6-coordinate nickel (II) complexes with three thiosemicarbazones and semicarbazone ligands, J. Inorg. Biochem., 2001, 84, 55–65 Search PubMed .
  20. R. Sharma, S. K. Agarwal, S. Rawat and M. Nagar, Synthesis, characterization and antibacterial activity of some transition metal cis 3,7-dimet-hyl-2,6 octadiensemicarbazone complexes, Transition Met. Chem., 2006, 31(2), 201–206 Search PubMed .
  21. H. Alshater, A. I. Al-Sulami, S. A. Aly, E. M. Abdalla, M. A. Sakr and S. S. Hassan, Antitumor and antibacterial activity of Ni(II), Cu(II), Ag(I), and Hg(II) complexes with ligand derived from thiosemicarbazones: Characterization and theoretical studies, Molecules, 2023, 28(2590), 1–18 Search PubMed .
  22. S. Datta, D. K. Seth, S. Gangopadhyay, P. Karmakar and S. Bhattacharya, Nickel complexes of some thiosemicarbazones: Synthesis, structure, catalytic properties and cytotoxicity studies, Inorg. Chim. Acta, 2012, 392, 118–130 Search PubMed .
  23. S. S. Renade and V. K. Panday, Transition metals in human cancer II, Sci. Total Environ., 1984, 40, 245–257 Search PubMed .
  24. D. Polo-Cerón, Cu(II) and Ni(II) complexes with new tridentate NNS thiosemicarbazones: synthesis, characterisation, DNA interaction, and antibacterial activity, Bioinorg. Chem. Appl., 2019, 2019, 1–14 Search PubMed .
  25. H. Karlsson, M. Fryknäs, S. Strese, J. Gullbo, G. Westman, U. Bremberg, T. Sjöblom, T. Pandzic, R. Larsson and P. Nygren, Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity, Oncotarget, 2017, 8(18), 30217–30234 Search PubMed .
  26. J. J. R. Fraústo da Silva and R. P. Williams, The biological chemistry of the elements, Chap. 15: The Inorganic Chemistry of Life, Oxónio, Clarendon Press, 2nd edn, 1991 Search PubMed .
  27. S. Shivhare and M. D. Gautam, Electrochemical study of complexes of Cu(II) and Ni(II) with thiosemicarbazone, J. Chem. Pharm. Res., 2011, 3(6), 1009–1016 Search PubMed .
  28. A. Bult, Metal Ions in Biological Systems, ed. Sigel, H., Marcel Dekker, New York, 1983, vol. 16, pp. 261–263 Search PubMed .
  29. E. Ülke, E. Hasanoğlu Özkan, D. Nartop and H. Ogutcu, New antimicrobial polymeric microspheres containing azomethine, J. Inorg. Organomet. Polym., 2022, 32, 3971–3982 Search PubMed .
  30. T. Amutha, M. Rameshbabu, S. Sasi Florence, N. Senthilkumar, I. Vetha Potheher and K. Prabha, Studies on structural and optical properties of pure and transition metals (Ni, Fe and co-doped Ni-Fe) doped tin oxide (SnO2) nanoparticles for anti-microbial activity, Res. Chem. Intermed., 2019, 45, 1929–1941 Search PubMed .
  31. D. Nartop, E. Hasanoğlu Özkan, H. Öğütçü and N. Kurnaz Yetim, Synthesis and in vitro biological assessments of novel thiazole-based thiosemicarbazone complexes, Duzce University Journal of Science and Technology, 2024, 12(3), 1389–1397 Search PubMed .
  32. H. Alshater, A. I. Al-Sulami, S. A. Aly, E. M. Abdalla, M. A. Sakr and S. S. Hassan, Antitumor and antibacterial activity of Ni(II), Cu(II), Ag(I), and Hg(II) complexes with ligand derived from thiosemicarbazones: Characterization and theoretical studies, Molecules, 2023, 28(6), 1–18 Search PubMed .
  33. R. M. Silverstein and F. X. Webster, Spectrometric Identification of Organic Compounds, John Wiley & Sons, New York, USA, 6th edn, 1998, vol. 11, pp. 160–166 Search PubMed .
  34. V. K. Maurya, L. B. Prasad, A. Singh, K. Shiv and A. Prasad, Synthesis, spectroscopic characterization, biological activity, and conducting properties of functionalized Ni(II) dithiocarbamate complexes with solvent extraction studies of the ligands, J. Sulfur Chem., 2022, 44(3), 336–353 Search PubMed .
  35. M. Hazra, T. Dolai, A. Pandey, S. K. Dey and A. Patra, Synthesis and characterisation of Copper(II) complexes with tridentate NNO functionalized ligand: density function theory study, DNA binding mechanism, optical properties, and biological application, Bioinorg. Chem. Appl., 2014, 2014, 1–14 Search PubMed .
  36. A. C. Tella and J. A. Obaleye, Copper(II) complexes of 4, 4- Diaminodiphenylsulphone: Synthesis, characterization and biological studies, E-J. Chem., 2009, 6(S1), S311–S323 Search PubMed .
  37. B. Atasever Arslan, B. Kaya, O. Şahin, S. Baday, C. C. Saylan and B. Ülküseven, The iron(III) and Nickel(II) complexes with tetradentate thiosemicarbazones: Synthesis, experimental, theoretical characterization, and antiviral effect against SARS-CoV-2, J. Mol. Struct., 2021, 1246(131166), 1–7 Search PubMed .
  38. L. V. Gavali, A. A. Mohammed, M. J. K. Al-Ogaili, S. H. Gaikwad, M. Kulkarni, R. Das and P. A. Ubale, Novel terephthalaldehyde bis(thiosemicarbazone) Schiff base ligand and its transition metal complexes as antibacterial Agents: Synthesis, characterization and biological investigations, Results Chem., 2024, 7(101316), 1–9 Search PubMed .
  39. M. V. Angelusiu, S. F. Barbuceanu, C. Draghici and G. L. Almajan, New Cu(II), Co(II), Ni(II) complexes with aroyl-hydrazone based ligand: Synthesis, spectroscopic characterization and in vitro antibacterial evaluation, Eur. J. Med. Chem., 2010, 45(5), 2055–2062 Search PubMed .
  40. E. Hasanoğlu Özkan and N. Sarı, Use of immobilized novel dendritic molecules as a marker for the detection of glucose in artificial urine, J. Mol. Struct., 2020, 1201(127134), 1–7 Search PubMed .
  41. A. Z. Macit, E. Hasanoğlu Özkan, H. Ogutcu and D. Nartop, Synthesis and in vitro antimicrobial evaluation of novel potent bioactive heterocyclic compounds, Polycyclic Aromat. Compd., 2023, 1–12 Search PubMed .
  42. S. Kocoglu, Z. Hayvalı and H. Ogutcu, A Polydentate ligand based on 2,2’-Dipyridylamine unit linked benzo-15-Crown-5; alkali and transition metal complexes; Photoresponsive ligand; antimicrobial evaluation against pathogenic microorganisms, Transition Met. Chem., 2021, 46(7), 509–522 Search PubMed .
  43. M. Ulular, N. Sarı, F. Han, H. Öğütcü and E. Hasanoğlu Özkan, Synthesis, antimicrobial, and DNA-binding evaluation of novel schiff bases containing tetrazole moiety and their Ni(II) and Pt(II) Complexes, Pharm. Chem. J., 2024, 57(10), 1609–1620 Search PubMed .
  44. D. Nartop, E. Tokmak, E. Hasanoğlu Özkan, H. E. Kızıl, H. Öğütcü, G. Ağar and S. Allı, Synthesis of novel polymers containing Schiff base as potential antimutagenic and antimicrobial agents, J. Med. Chem. Sci., 2020, 4(3), 363–372 Search PubMed .
  45. D. Drzewiecka, Significance and roles of Proteus spp. bacteria in natural environments, Microb. Ecol., 2016, 72(4), 741–758 Search PubMed .
  46. J. P. S. Cabral, Water microbiology. Bacterial pathogens and water, Int. J. Environ. Res. Public Health, 2010, 7(10), 3657–3703 Search PubMed .
  47. H. Carolus, K. V. Dyck and P. V. Dijck, Candida albicans and Staphylococcus species: A threatening twosome, Front. Microbiol., 2019, 10(2162), 1–8 Search PubMed .
  48. V. A. Kumar, Y. Sarala, A. Siddikha, S. Vanitha, S. Babu and A. V. Reddy, Synthesis, characterization antimicrobial and antioxidant activities of 2,4-dihydroxybenzaldehyde-4-phenyl-3-thiosemicarbazone (DHBPTSC) and its Pd(II), Ni(II)dppm mixed ligand and Cu(II) complex having heterocyclic bases, J. Appl. Pharm. Sci., 2018, 8(4), 071–078 Search PubMed .
  49. P. Jain, S. Sharma, N. Kumar and N. Misra, Ni(II) and Cu(II) complexes of bidentate thiosemicarbazone ligand: Synthesis, structural, theoretical, biological studies and molecular modeling, Appl. Organomet. Chem., 2020, 34, 9 Search PubMed .

Footnote

Electronic supplementary information (ESI) available. See DOI: https://doi.org/10.1039/d4ra04002c

This journal is © The Royal Society of Chemistry 2024